ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).
Prostate Cancer
DRUG: TOK-001|DRUG: TOK-001|DRUG: TOK-001|DRUG: TOK-001|DRUG: TOK-001|DRUG: TOK-001|DRUG: TOK-001|DRUG: TOK-001
Phase 1: Incidence of adverse events, Safety will be assessed by incidence of AEs and change from baseline in the following additional safety parameters: clinical laboratory assessments, physical examination, vital signs, and 12 lead electrocardiograms (ECGs), 3 months
Efficacy Measures, Efficacy will be assessed by evaluation of change in PSA level, changes from baseline in CT/MRI and bone scans, response rate RECIST criteria and additional special laboratories, 3 months
The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).